No cure available for exposure to potentially deadly ionizing radiation
- UVA researchers have identified compounds that could lead to the first antidote for potentially deadly radiation exposure
- Research was spurred by government concern about terror attacks and nuclear accidents
- For people exposed to sufficient ionizing radiation, doctors can only try to ease their suffering until death
- 2016 is the 30th anniversary of the Chernobyl nuclear accident and the fifth anniversary of the Fukushima nuclear accident
University of Virginia School of Medicine researchers have identified promising drugs that could lead to the first antidote for radiation exposure that might result from a dirty bomb terror attack or a nuclear accident such as Chernobyl.
Some of the compounds, including the drug rapamycin, have previously been shown to extend life in organisms such as worms and flies, though it’s unknown if they would have the same benefit in humans. UVA’s research suggests that these compounds, or similar drugs, might counter the deadly effects of ionizing radiation.
Currently there is no treatment for people exposed to lethal doses of radiation; doctors can only try to ease their suffering until death. “If you’re exposed to a very, very high dose, it’s rapid deterioration and immediate death,” explained John S. Lazo, PhD, of UVA’s Department of Pharmacology. “It’s the lower doses that people – particularly governments – are concerned about. The type of exposure that might result from a dirty bomb or a nuclear accident. How do we alleviate the effects? What’s the antidote? Right now, we just don’t have anything.”
Innovative Approach
Lazo and his colleague Elizabeth R. Sharlow, PhD, screened a library of more than 3,400 existing drugs, vitamins and other compounds to identify ones that might help cells withstand the effects of radiation exposure. The goal was to keep stem cells – the cells that produce the various cell types in the body – alive long enough to repair the damage caused by radiation.
“We wanted to find already approved drugs that would potentially keep stem cells, or progenitor cells, alive after radiation exposure,” Sharlow said. “That’s very much of interest to the NIH [National Institutes of Health] right now: How can we keep those self-renewing populations alive so they can actually help heal the effects of radiation exposure?”
After they identified potential leads, Sharlow created 3D computer models to compare the substances’ chemical structures. That analysis identified a cluster of promising compounds with similar structures – a tantalizing lead in the quest for an antidote. “If you’re a drug hunter, the way we are, this is really cool information,” Lazo said. “Because you can say, ‘Now I will look in the universe of 40 million compounds. What else looks like that? Are they useful?'”
He noted that it is unlikely any one drug or compound will work on its own. “A lot of us in this field think it will be a cocktail of things you take,” he said. “And if you think you need cocktails, you need the individual ingredients. That’s why we think this is pretty important – because it’s providing new ingredients for that cocktail.”
Learn more: Amid terror threats, new hope for radiation antidote
The Latest on: Radiation antidote
[google_news title=”” keyword=”radiation antidote” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Radiation antidote
- Leading Radiation Oncologist Dr. Steven E. Finkelstein Joins Associated Medical Professionals of NY, an Affiliate of U.S. Urology Partnerson April 30, 2024 at 3:38 am
U.S. Urology Partners affiliate A.M.P. in Central NY adds internationally recognized radiation oncologist and researcher Dr. Steven E. Finkelstein.
- Science & Medicine: Revolutionizing prostate cancer treatmenton April 29, 2024 at 2:26 pm
Prostate cancer is the most common cancer diagnosed in men, and the five year survival rate is 97%.
- Advanced Cancer Care Close To Homeon April 27, 2024 at 5:00 pm
Through Ann B. Barshinger Cancer Institute’s integration with Penn Medicine’s Roberts Proton Center in Philadelphia, Ann B. Barshinger Cancer Institute patients throughout Pennsylvania have access to ...
- What causes radiation sickness, know its symptoms and causeson April 27, 2024 at 4:19 am
Radiation sickness, also known as acute radiation syndrome (ARS), is a severe condition that arises from exposure to high levels of ionizing..|News Track ...
- SGMC Health expands training for physicianson April 26, 2024 at 1:09 pm
SGMC Health is expanding its graduate medical education program with a new residency starting in July of 2025. In March, the health system received accreditation by the Accreditation ...
- WVU Medicine leaders reveal more details about planned projectson April 23, 2024 at 5:08 pm
The emergency department will be erected at the Behavioral Health Pavilion of the Virginias located in Bluefield while the cancer center will be built at the hospital’s main campus in Princeton.
- Key measures outlined for patient radiation protection in new era of medical imagingon April 23, 2024 at 3:59 am
Meeting participants agreed that with the current pace of technological developments, there is an increasing urgency to update referral guidelines, optimization mechanisms, protocols and regulations.
- How tardigrades can survive intense radiationon April 20, 2024 at 9:48 am
Researchers have discovered that tardigrades -- microscopic animals famed for surviving harsh extremes -- have an unusual response to radiation.
- Novel Oral Synthetic Genistein Nanosuspension May Protect Against Negative Effects Of Radiation Therapy In Lung Canceron April 20, 2024 at 8:12 am
BIO 300 use led to reduced levels of a proinflammatory/profibrotic cytokine associated with lung injury from radiation therapy. BIO 300 did not interfere with the pharmacokinetics of chemotherapy, did ...
- Humanetics Corporation: BIO 300 Synthetic Genistein Nanosuspension May Protect Against Negative Effects Of Radiation Therapy In Lung Cancer Patientson April 18, 2024 at 5:31 am
BIO 300 use led to reduced levels of a proinflammatory/profibrotic cytokine associated with lung injury from radiation therapy. BIO 300 did not interfere with the pharmacokinetics of chemotherapy, did ...
via Bing News